Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Volitionrx reports robust Q3 revenue growth and strategic advancements

Volitionrx Limited demonstrated strong performance in revenue growth, innovation, and financial progress.
Key strengths include successful product sales, research advancements, and strategic financial planning.
Challenges in market dynamics and cost management require strategic focus and operational efficiency improvements.
Opportunities for growth exist in market expansion, cost optimization, new partnerships, and research publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

HENDERSON, Nev. , March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Volition appoints Dr Andrew Retter as Chief Medical Officer

HENDERSON, Nev. , Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

Catalyst Pharmaceuticals

Estrella Immunopharma Inc

The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.

VolitionRx has 'compelling plans' to advance veterinary care in 2024

HENDERSON, Nev. , Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.

Volition Issues Business Review 2023

VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective introduction of the diagnostic solution into clinical practice.

Volition secures €5M in financing from Belgium's Wallonie Entreprendre

HENDERSON, Nev. , Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A.

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Tim Moore - EF Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) said its Nu.Q Vet Cancer Test revenue has seen a nearly five-fold increase in sales over the first nine months of 2023 compared to the same period last year. The Nu.Q test involves analyzing nucleosomes, which are structural units of DNA, to identify specific patterns or changes associated with the presence of cancer in animals.

VolitionRx's Nu.Q Vet Cancer Test sees five-fold revenue surge in 2023

Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update

Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update

VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland. The NuQ Vet Cancer Test is a groundbreaking tool for the early detection and monitoring of cancer in dogs and VPG will be the first-to-market diagnostics laboratory in the UK to offer the test, the company said.

VolitionRx joins up with VPG to launch Nu.Q Vet Cancer Test in UK and Ireland

HENDERSON, Nev. , Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland

HENDERSON, Nev. , Oct. 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and it could play a vital role in sepsis prognosis. The paper is about a 150-patient study led by Professor Guillaume Monneret, Head of Clinical Immunology Laboratory at Hospices Civils de Lyon in France.

VolitionRx highlights study demonstrating Nu.Q NETs is promising biomarker for septic shock

HENDERSON, Nev. , Oct. 19, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.

Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock

VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to the Kingdom of Belgium, for an exclusive tour of its state-of-the-art research, development, and manufacturing facilities located in Isnes, Belgium. "Ambassador Adler's visit today was an ideal opportunity for us to celebrate this collaborative work and highlight the close ties we have fostered between US and Belgian stakeholders over the last 13 years,” Gaetan Michel, Volition's COO said in a statement.

VolitionRx welcomes US Ambassador to Belgium for exclusive tour of research facilities

HENDERSON, Nev. , Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M.

US Ambassador Adler visits Belgian Volition

VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection tools at the annual congress of the European Society for Medical Oncology (ESMO) 2023. "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma and introduce what we believe to be an entirely new method for the detection of cancer,” Volition's chief scientific officer Dr. Jake Micallef said in a statement.

VolitionRx to present cancer detection abstracts at European oncology conference

HENDERSON, Nev. , Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology.

Volition Presents Three Cancer Detection Abstracts at ESMO 2023

VolitionRx (NYSE-A:VNRX) has revealed insights from a recent Key Opinion Leader (KOL) roundtable focused on sepsis management. The KOL roundtable brought together a panel of leading experts in sepsis to discuss the potential of leveraging Volition's Nu.Q NETs technology in clinical practice.

VolitionRx holds roundtable on sepsis management

HENDERSON, Nev. , Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader ("KOL") roundtable on sepsis management.

News for Volitionrx Limited Stock (VNRX)